Revolution Medicines RVMD 深 滬
等待開盤 10-08 09:30:00 美东时间
200.87
+1.000
+0.50%
華盛通- 最 高203.50
- 今 開198.18
- 成交量 118.52万股
- 最 低 196.25
- 昨 收 199.87
- 總市值 430.54亿
- 52周最高 224.31
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 52.48
- 委 比 -96.99%
- 總股本 2.14亿
- 歷史最高 224.31
- 量 比 0.69
- 振 幅 3.63%
- 歷史最低 14.08
- 每 手 1
- 風險率 52.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股夜盘 | Onto Innovation小升1.75%，美国再保险集团小升1.67%
阿里拉姆制药小跌1.65%；Revolution Medicines小跌1.58%；安特吉小跌1.49%
10-06 08:06
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 cli...
10-05 20:02
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines has initiated the RASolute 309 Phase 3 trial evaluating the combination of RASONQUE and zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma. This trial aims to address the high unmet need in this patient population, as current five-year survival rates are less than 3%. RASONQUE, an FDA-approved RAS(ON) multi-selective inhibitor, and zoldonrasib, a G12D-selective inhibitor, showed promising ...
10-05 12:00
内部人交易｜Revolution Medicines披露一笔股票减持，金额约15.86万美元
美股上市公司Revolution Medicines（RVMD）披露一笔内部人股票交易。文件显示，公司内部人Cislini (Jeffrey Todd)（Of...
10-01 07:01
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the com...
09-28 20:00
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
Nvidia-backed AI drugmaker Iambic Therapeutics seeks U.S. listing
Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia (NVDA), filed for a U.S. initial public offering on Monday, seeking to list on the Nasdaq under the ticker IAM. The San Diego-...
09-22 12:44
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
09-22 01:38
